Avalo Therapeutics (AVTX) Competitors $10.90 -0.15 (-1.36%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends AVTX vs. CADL, LIFE, ASMB, SBBP, NLTX, SIGA, FHTX, KRRO, SLRN, and ARCTShould you be buying Avalo Therapeutics stock or one of its competitors? The main competitors of Avalo Therapeutics include Candel Therapeutics (CADL), aTyr Pharma (LIFE), Assembly Biosciences (ASMB), Strongbridge Biopharma (SBBP), Neoleukin Therapeutics (NLTX), SIGA Technologies (SIGA), Foghorn Therapeutics (FHTX), Korro Bio (KRRO), Acelyrin (SLRN), and Arcturus Therapeutics (ARCT). These companies are all part of the "medical" sector. Avalo Therapeutics vs. Candel Therapeutics aTyr Pharma Assembly Biosciences Strongbridge Biopharma Neoleukin Therapeutics SIGA Technologies Foghorn Therapeutics Korro Bio Acelyrin Arcturus Therapeutics Candel Therapeutics (NASDAQ:CADL) and Avalo Therapeutics (NASDAQ:AVTX) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, community ranking, valuation, dividends, analyst recommendations, media sentiment, earnings and profitability. Which has preferable earnings & valuation, CADL or AVTX? Avalo Therapeutics has higher revenue and earnings than Candel Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCandel Therapeutics$120K1,079.96-$37.94M-$1.73-2.31Avalo Therapeutics$1.92M58.98-$31.54MN/AN/A Is CADL or AVTX more profitable? Avalo Therapeutics' return on equity of -442.16% beat Candel Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Candel TherapeuticsN/A -629.29% -173.39% Avalo Therapeutics N/A -442.16%122.99% Which has more volatility and risk, CADL or AVTX? Candel Therapeutics has a beta of -0.88, indicating that its share price is 188% less volatile than the S&P 500. Comparatively, Avalo Therapeutics has a beta of 1.03, indicating that its share price is 3% more volatile than the S&P 500. Does the MarketBeat Community favor CADL or AVTX? Candel Therapeutics received 4 more outperform votes than Avalo Therapeutics when rated by MarketBeat users. Likewise, 52.94% of users gave Candel Therapeutics an outperform vote while only 29.41% of users gave Avalo Therapeutics an outperform vote. CompanyUnderperformOutperformCandel TherapeuticsOutperform Votes952.94% Underperform Votes847.06% Avalo TherapeuticsOutperform Votes529.41% Underperform Votes1270.59% Does the media refer more to CADL or AVTX? In the previous week, Candel Therapeutics had 15 more articles in the media than Avalo Therapeutics. MarketBeat recorded 16 mentions for Candel Therapeutics and 1 mentions for Avalo Therapeutics. Avalo Therapeutics' average media sentiment score of 1.00 beat Candel Therapeutics' score of 0.46 indicating that Avalo Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Candel Therapeutics Neutral Avalo Therapeutics Positive Do analysts prefer CADL or AVTX? Candel Therapeutics currently has a consensus price target of $11.00, suggesting a potential upside of 175.69%. Given Candel Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Candel Therapeutics is more favorable than Avalo Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Candel Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Avalo Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50 Do insiders and institutionals hold more shares of CADL or AVTX? 13.9% of Candel Therapeutics shares are owned by institutional investors. Comparatively, 87.1% of Avalo Therapeutics shares are owned by institutional investors. 41.6% of Candel Therapeutics shares are owned by company insiders. Comparatively, 0.3% of Avalo Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. SummaryCandel Therapeutics and Avalo Therapeutics tied by winning 7 of the 14 factors compared between the two stocks. Ad Wyatt Investment ResearchMy #1 Pre IPO Trade for 2025 – NAME and TICKEROne tiny company... Could quickly become "the next SpaceX." It plans to go public on the NASDAQ. And today you can buy Pre-IPO shares for less than $4.00. Get urgent details inside this free report...The Next SpaceX Pre-IPO Get Avalo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for AVTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart AVTX vs. The Competition Export to ExcelMetricAvalo TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$113.25M$6.49B$5.07B$8.90BDividend YieldN/A8.11%4.99%4.07%P/E RatioN/A4.8587.8613.46Price / Sales58.98374.821,228.8287.66Price / CashN/A52.5939.5136.27Price / Book5.3710.216.946.30Net Income-$31.54M$153.61M$119.12M$225.93M7 Day Performance-19.14%-2.00%-1.84%-1.32%1 Month Performance-5.13%-7.47%-3.65%0.60%1 Year Performance-49.54%31.80%31.64%26.23% Avalo Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)AVTXAvalo Therapeutics2.3577 of 5 stars$10.90-1.4%N/A-47.4%$113.25M$1.92M0.0040Positive NewsCADLCandel Therapeutics1.8165 of 5 stars$3.99+0.3%$11.00+175.7%+347.1%$129.60M$120,000.000.0060Analyst ForecastAnalyst RevisionNews CoverageLIFEaTyr Pharma1.7033 of 5 starsN/A$25.50+∞N/A$131.12M$350,000.00-2.1156Analyst ForecastASMBAssembly Biosciences4.1387 of 5 stars$14.49-3.5%$35.00+141.5%+86.5%$92.16M$7.16M0.00100SBBPStrongbridge BiopharmaN/A$2.00flatN/A+0.0%$135.66M$30.73M-2.5672Analyst ForecastGap DownNLTXNeoleukin TherapeuticsN/A$15.33-11.0%N/A+30.5%$144.07MN/A-4.9390High Trading VolumeSIGASIGA Technologies0.9671 of 5 stars$6.30+0.8%N/A+20.9%$449.82M$139.92M5.2140Analyst RevisionFHTXFoghorn Therapeutics2.655 of 5 stars$7.99+1.7%$16.00+100.3%+91.2%$444.16M$34.15M0.00120KRROKorro Bio2.7373 of 5 stars$47.00+0.8%$142.17+202.5%+24.8%$440.39M$14.07M0.0070Analyst RevisionSLRNAcelyrin3.3895 of 5 stars$4.38-1.1%$11.50+162.6%-50.2%$439.45MN/A-1.80135Analyst RevisionPositive NewsARCTArcturus Therapeutics2.0686 of 5 stars$16.12-0.3%$71.40+342.9%-33.7%$436.69M$169.93M-7.28180 Related Companies and Tools Related Companies Candel Therapeutics Competitors aTyr Pharma Competitors Assembly Biosciences Competitors Strongbridge Biopharma Competitors Neoleukin Therapeutics Competitors SIGA Technologies Competitors Foghorn Therapeutics Competitors Korro Bio Competitors Acelyrin Competitors Arcturus Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:AVTX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avalo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avalo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free AVTX Stock Alerts